G. A. Martini, C. J. Peters, and J. W. Peters, Marburg virus disease, Clinical syndrome An introduction to Ebola: the virus and the disease, Journal of Infectious Diseases, vol.179, issue.21, pp.1-9, 1971.

K. M. Johnson, J. V. Lange, P. A. Webb, and F. A. Murphy, Isolation and partial characterization of a new virus causing acute haemorrhagic fever in Zaire, The Lancet, pp.309-569, 1977.

C. G. Hayes, J. P. Burans, T. G. Ksiazek, D. Rosario, R. A. Miranda et al., Outbreak of fatal illness among captive macaques in the Philippines caused by an Ebola-related filovirus, The American journal of tropical medicine and hygiene, pp.46-664, 1992.

E. M. Leroy, A. Epelboin, V. Mondonge, X. Pourrut, J. P. Gonzalez et al., Human Ebola Outbreak Resulting from Direct Exposure to Fruit Bats in Luebo, Democratic Republic of Congo, 2007, Vector-Borne and Zoonotic Diseases, vol.9, issue.6, pp.723-728, 2007.
DOI : 10.1089/vbz.2008.0167

URL : https://hal.archives-ouvertes.fr/hal-00399906

C. F. Basler and G. K. Amarasinghe, Evasion of Interferon Responses by Ebola and Marburg Viruses, Journal of Interferon & Cytokine Research, vol.29, issue.9, pp.511-520, 2009.
DOI : 10.1089/jir.2009.0076

F. Villinger, P. E. Rollin, S. S. Brar, N. F. Chikkala, J. Winter et al., Markedly Elevated Levels of Interferon (IFN)?????, IFN?????, Interleukin (IL)???2, IL???10, and Tumor Necrosis Factor????? Associated with Fatal Ebola Virus Infection, The Journal of Infectious Diseases, vol.179, issue.s1, pp.188-191, 1999.
DOI : 10.1086/514283

Y. Wang, Z. Liu, and Q. Dai, A highly immunogenic fragment derived from Zaire Ebola virus glycoprotein elicits effective neutralizing antibody, Virus research, pp.254-261, 2014.

N. J. Sullivan, T. W. Geisbert, J. B. Geisbert, D. J. Shedlock, L. Xu et al., Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs, PLoS Medicine, vol.79, issue.6, p.177, 2006.
DOI : 10.1371/journal.pmed.0030177.sd001

S. M. Jones, H. Feldmann, U. Ströher, J. B. Geisbert, L. Fernando et al., Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses, Nature Medicine, vol.179, issue.7, pp.11-786, 2005.
DOI : 10.1016/S0140-6736(82)91871-2

A. M. Henao-restrepo, I. M. Longini, M. Egger, N. E. Dean, W. J. Edmunds et al., Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial, The Lancet, vol.386, issue.9996, pp.386-857, 2015.
DOI : 10.1016/S0140-6736(15)61117-5

J. S. Gear, G. A. Cassel, A. J. Gear, B. Trappler, L. Clausen et al., Outbreak of Marburg virus disease in Johannesburg, British Medical Journal, vol.13, issue.45995, pp.489-493, 1975.

D. H. Smith, M. Isaacson, K. M. Johnson, A. Bagshawe, B. K. Johnson et al., Marburg-virus disease in Kenya, The Lancet, pp.319-816, 1982.

E. D. Johnson, B. K. Johnson, D. Silverstein, P. Tukei, T. W. Geisbert et al., Characterization of a new Marburg virus isolated from a, pp.101-114, 1987.

R. Colebunders, A. Tshomba, M. D. Van-kerkhove, D. G. Bausch, P. Campbell et al., Marburg Hemorrhagic Fever in Durba and Watsa, Democratic Republic of the Congo: Clinical Documentation, Features of Illness, and Treatment, The Journal of Infectious Diseases, vol.196, issue.s2, pp.148-153, 2007.
DOI : 10.1086/520543

K. M. Johnson, Ebola hemorrhagic fever in Zaire, Bulletin of the World Health Organization, vol.56, issue.2, pp.271-293, 1976.

D. I. Smith, Ebola hemorrhagic fever in Sudan, Bulletin of the World Health Organization, vol.56, issue.2, pp.247-270, 1976.

H. Feldmann and T. W. Geisbert, Ebola haemorrhagic fever, The Lancet, pp.849-862, 2011.

R. C. Baron, J. B. Mc-cormick, and O. A. Zubeir, Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread, Bulletin of the World Health Organization, issue.6, pp.61-997, 1983.

P. B. Jahrling, T. W. Geisbert, D. W. Dalgard, and E. D. Johnson, Preliminary report: isolation of Ebola virus from monkeys imported to USA, The Lancet, vol.335, issue.8688, pp.335-502, 1990.
DOI : 10.1016/0140-6736(90)90737-P

M. E. Miranda and N. L. Miranda, Reston ebolavirus in Humans and Animals in the Philippines: A Review, Journal of Infectious Diseases, vol.204, issue.suppl 3, pp.757-760, 2011.
DOI : 10.1093/infdis/jir296

G. A. Marsh, J. Haining, R. Robinson, and A. Foord, Ebola Reston Virus Infection of Pigs: Clinical Significance and Transmission Potential, Journal of Infectious Diseases, vol.204, issue.suppl 3, pp.804-809, 2011.
DOI : 10.1093/infdis/jir300

P. Formenty, C. Boesch, M. Wyers, and C. Steiner, Ebola Virus Outbreak among Wild Chimpanzees Living in a Rain Forest of Cote d'Ivoire, The Journal of Infectious Diseases, vol.179, issue.s1, pp.120-126, 1999.
DOI : 10.1086/514296

P. Formenty, C. Hatz, L. Guenno, B. Stoll, and A. , Human Infection Due to Ebola Virus, Subtype C??te d'Ivoire: Clinical and Biologic Presentation, The Journal of Infectious Diseases, vol.179, issue.s1, pp.48-53, 1999.
DOI : 10.1086/514285

A. S. Khan, F. Kweteminga-tshioko, D. L. Heymann, L. Guenno, and B. , The Reemergence of Ebola Hemorrhagic Fever, Democratic Republic of the Congo, 1995, The Journal of Infectious Diseases, vol.179, issue.s1, pp.76-86, 1995.
DOI : 10.1086/514306

A. J. Georges, E. M. Leroy, A. A. Renaut, and C. Tevi-benissan, Ebola Hemorrhagic Fever Outbreaks in Gabon, 1994???1997: Epidemiologic and Health Control Issues, The Journal of Infectious Diseases, vol.179, issue.s1, pp.65-75, 1994.
DOI : 10.1086/514290

E. M. Leroy, S. Souquière, P. Rouquet, and D. Drevet, Re-emergence of ebola haemorragic fever in Gabon, Lancet, issue.9307, pp.359-712, 2002.

X. Pourrut, B. Kumulungui, T. Wittmann, and G. Moussavou, The natural history of Ebola virus in Africa, Microbes and Infection, vol.7, issue.7-8, pp.1005-1014, 2005.
DOI : 10.1016/j.micinf.2005.04.006

P. Roddy, N. Howard, M. D. Van-kerkhove, J. Lutwama, T. Shoemaker et al., Clinical Manifestations and Case Management of Ebola Haemorrhagic Fever Caused by a Newly Identified Virus Strain, Emerging Infectious Disease, pp.52986-2011, 2007.

C. G. Albarino, T. Shoemaker, M. L. Khristova, J. F. Wamala, J. J. Muyembe et al., Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012, Virology, vol.442, issue.2, pp.442-97, 2013.
DOI : 10.1016/j.virol.2013.04.014

A. Negredo, G. Palacios, S. Vázquez-morón, F. González, S. A. Carroll et al., Discovery of an Ebolavirus-Like Filovirus in Europe, PLoS Pathogens, vol.7, issue.10, pp.1002304-1002351, 2011.
DOI : 10.1371/journal.ppat.1002304.s005

A. A. Bukreyev, K. Chandran, O. Dolnik, J. M. Dye, H. Ebihara et al., Discussions and decisions of the 2012???2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012???June 2013, Discussions and decisions of the 2012?2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, pp.821-830, 2012.
DOI : 10.1007/s00705-013-1846-9

. Center-for-disease, . Control, . Cdc-), and C. Goldsmith, Public Health Image Library, 1832.

G. Viralzone, A. Sanchez, M. P. Kiley, B. P. Holloway, and D. D. Auperin, Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus, Virus research, vol.29, issue.3, pp.215-240, 1993.

L. H. Elliott, M. P. Kiley, and J. B. Mccormick, Descriptive analysis of Ebola virus proteins, Virology, vol.147, issue.1, pp.169-176, 1985.
DOI : 10.1016/0042-6822(85)90236-3

V. E. Volchkov, H. Feldmann, V. A. Volchkova, and H. D. Klenk, Processing of the Ebola virus glycoprotein by the proprotein convertase furin, Proceedings of the National Academy of Sciences, pp.95-5762, 1998.
DOI : 10.1073/pnas.95.10.5762

W. Weissenhorn, A. Carfí, K. H. Lee, J. J. Skehel, and D. C. Wiley, Crystal Structure of the Ebola Virus Membrane Fusion Subunit, GP2, from the Envelope Glycoprotein Ectodomain, Molecular Cell, vol.2, issue.5, pp.605-616, 1998.
DOI : 10.1016/S1097-2765(00)80159-8

S. Moller-tank, W. Maury, V. E. Volchkov, V. A. Volchkova, and O. Dolnik, Ebola Virus Entry: A Curious and Complex Series of Events, PLOS Pathogens, vol.344, issue.9, p.1004731, 2005.
DOI : 10.1371/journal.ppat.1004731.g003

A. Sanchez, S. G. Trappier, B. W. Mahy, C. J. Peters, and S. T. Nichol, The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing., Proceedings of the National Academy of Sciences, pp.93-3602, 1996.
DOI : 10.1073/pnas.93.8.3602

C. P. Alvarez, F. Lasala, J. Carrillo, O. Muñiz, A. L. Corbí et al., Ctype lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans, Journal of virology, issue.13, pp.76-6841, 2002.

S. Y. Chan, M. C. Ma, and M. A. Goldsmith, Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses, Journal of General Virology, vol.81, issue.9, pp.81-2155, 2000.
DOI : 10.1099/0022-1317-81-9-2155

N. J. Sullivan, M. Peterson, Z. Y. Yang, W. P. Kong, H. Duckers et al., Ebola Virus Glycoprotein Toxicity Is Mediated by a Dynamin-Dependent Protein-Trafficking Pathway, Journal of Virology, vol.79, issue.1, pp.547-553, 2005.
DOI : 10.1128/JVI.79.1.547-553.2005

N. Alazard-dany, V. Volchkova, O. Reynard, C. Carbonnelle, O. Dolnik et al., Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level, Journal of General Virology, vol.87, issue.5, pp.1247-1257, 2006.
DOI : 10.1099/vir.0.81361-0

O. Dolnik, V. A. Volchkova, B. Escudero-perez, P. Lawrence, H. D. Klenk et al., Shedding of Ebola Virus Surface Glycoprotein Is a Mechanism of Self-regulation of Cellular Cytotoxicity and Has a Direct Effect on Virus Infectivity, Journal of Infectious Diseases, vol.212, issue.suppl 2, p.268, 2015.
DOI : 10.1093/infdis/jiv268

L. Xu, A. Sanchez, Z. Y. Yang, S. R. Zaki, E. G. Nabel et al., Immunization for Ebola virus infection, Nature Medicine, vol.3, issue.1, pp.37-42, 1998.
DOI : 10.1038/sj.gt.3300403

J. E. Ledgerwood, P. Costner, N. Desai, L. Holman, M. E. Enama et al., A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults, Vaccine, vol.29, issue.2, pp.29-304, 2010.
DOI : 10.1016/j.vaccine.2010.10.037

M. Garbutt, R. Liebscher, V. Wahl-jensen, S. Jones, P. Möller et al., Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses, Journal of Virology, vol.78, issue.10, pp.78-5458, 2004.
DOI : 10.1128/JVI.78.10.5458-5465.2004

O. Reynard, M. Borowiak, V. A. Volchkova, S. Delpeut, M. Mateo et al., Ebolavirus Glycoprotein GP Masks both Its Own Epitopes and the Presence of Cellular Surface Proteins, Journal of Virology, vol.83, issue.18, pp.83-9596, 2009.
DOI : 10.1128/JVI.00784-09

K. Yaddanapudi, G. Palacios, J. S. Towner, I. Chen, C. A. Sariol et al., Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses, The FASEB Journal, vol.20, issue.14, pp.20-2519, 2006.
DOI : 10.1096/fj.06-6151com

H. Ito, S. Watanabe, A. Takada, and Y. Kawaoka, Ebola Virus Glycoprotein: Proteolytic Processing, Acylation, Cell Tropism, and Detection of Neutralizing Antibodies, Journal of Virology, vol.75, issue.3, pp.75-1576, 2001.
DOI : 10.1128/JVI.75.3.1576-1580.2001

G. S. Mohan, W. Li, L. Ye, R. W. Compans, and C. Yang, Antigenic Subversion: A Novel Mechanism of Host Immune Evasion by Ebola Virus, PLoS Pathogens, vol.422, issue.3, p.1003065, 2012.
DOI : 10.1371/journal.ppat.1003065.s005

L. De, M. A. Vega, G. Wong, G. P. Kobinger, and X. Qiu, The multiple roles of sGP in Ebola pathogenesis, Viral Immunology, vol.28, issue.1, pp.3-9, 2015.

V. M. Wahl-jensen, T. A. Afanasieva, J. Seebach, U. Ströher, H. Feldmann et al., Effects of Ebola Virus Glycoproteins on Endothelial Cell Activation and Barrier Function, Journal of Virology, vol.79, issue.16, pp.79-10442, 2005.
DOI : 10.1128/JVI.79.16.10442-10450.2005

A. Iwasa, M. Shimojima, and Y. Kawaoka, sGP Serves as a Structural Protein in Ebola Virus Infection, Journal of Infectious Diseases, vol.204, issue.suppl 3, pp.897-903, 2011.
DOI : 10.1093/infdis/jir313

J. Sui and W. A. Marasco, Evidence against Ebola Virus sGP Binding to Human Neutrophils by a Specific Receptor, Virology, vol.303, issue.1, pp.9-14, 2002.
DOI : 10.1006/viro.2002.1715

L. De, M. A. Vega, D. Stein, and G. P. Kobinger, Ebolavirus evolution: past and present, PLoS Pathogens, issue.11, pp.11-1005221, 2015.

H. Ebihara, A. Takada, D. Kobasa, S. Jones, G. Neumann et al., Molecular Determinants of Ebola Virus Virulence in Mice, PLoS Pathogen, p.73, 2006.
DOI : 1098-5514(2001)075[5205:EVVPFA]2.0.CO;2

M. Mateo, C. Carbonnelle, O. Reynard, L. Kolesnikova, K. Nemirov et al., VP24 Is a Molecular Determinant of Ebola Virus Virulence in Guinea Pigs, Journal of Infectious Diseases, vol.204, issue.suppl 3, pp.1011-1020, 2011.
DOI : 10.1093/infdis/jir338

C. L. Althaus, Estimating the Reproduction Number of Ebola Virus (EBOV) During the 2014 Outbreak in West Africa, PLoS Currents, vol.6, 2014.
DOI : 10.1371/currents.outbreaks.91afb5e0f279e7f29e7056095255b288

M. Côté and J. M. Cunningham, L'entrée du virus Ébola et Marburg : interaction entre la glycoprotéine virale et les facteurs cellulaires, John Libbey Eurotext, vol.16, issue.3, pp.168-177, 2012.

R. J. Wool-levis and P. Bates, Characterization of Ebola Virus Entry by Using Pseudotyped Viruses: Identification of Receptor-Deficient Cell Lines, Journal of Virology, vol.72, issue.4, pp.3155-3160, 1998.

R. B. Martines, L. D. Ng, P. W. Greer, and P. E. Rollin, Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses, The Journal of Pathology, vol.345, issue.2, pp.153-174, 2015.
DOI : 10.1002/path.4456

G. Simmonsa, J. D. Reevesa, C. C. Groganb, and L. H. Vandenberghec, DC-SIGN and DC-SIGNR Bind Ebola Glycoproteins and Enhance Infection of Macrophages and Endothelial Cells, Virology, vol.305, issue.1, pp.305-115, 2003.
DOI : 10.1006/viro.2002.1730

M. Shimojima, A. Takada, H. Ebihara, and G. Neumann, Tyro3 Family-Mediated Cell Entry of Ebola and Marburg Viruses, Journal of Virology, vol.80, issue.20, pp.80-10109, 2006.
DOI : 10.1128/JVI.01157-06

S. Y. Chan, C. J. Empig, F. J. Welte, and F. Roberto, Folate Receptor-?? Is a Cofactor for Cellular Entry by Marburg and Ebola Viruses, Cell, vol.106, issue.1, pp.117-126, 2001.
DOI : 10.1016/S0092-8674(01)00418-4

S. Bhattacharyyaa, K. L. Warfieldc, G. Ruthelc, and S. Bavaric, Ebola virus uses clathrin-mediated endocytosis as an entry pathway, Virology, vol.401, issue.1, pp.401-419, 2010.
DOI : 10.1016/j.virol.2010.02.015

C. J. Empig and M. A. Goldsmith, Association of the Caveola Vesicular System with Cellular Entry by Filoviruses, Journal of Virology, vol.76, issue.10, pp.76-5266, 2002.
DOI : 10.1128/JVI.76.10.5266-5270.2002

A. Nanbo, I. Masaki, S. Watanabe, and . Noda, Ebolavirus Is Internalized into Host Cells via Macropinocytosis in a Viral Glycoprotein-Dependent Manner, PLoS Pathogens, vol.282, issue.9, pp.1001121-96, 2008.
DOI : 10.1371/journal.ppat.1001121.s027

M. A. Brindley, C. L. Hunt, A. S. Kondratowicz, and J. Bowman, Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein, Virology, vol.415, issue.2, pp.415-83, 2011.
DOI : 10.1016/j.virol.2011.04.002

S. Moller-tank, A. S. Kondratowicz, R. A. Davey, and P. D. Rennert, Role of the Phosphatidylserine Receptor TIM-1 in Enveloped-Virus Entry, Journal of Virology, vol.87, issue.15, pp.8327-8341, 2013.
DOI : 10.1128/JVI.01025-13

K. Schornberg, S. Matsuyama, K. Kabsch, and S. Delos, Role of Endosomal Cathepsins in Entry Mediated by the Ebola Virus Glycoprotein, Journal of Virology, vol.80, issue.8, pp.80-4174, 2006.
DOI : 10.1128/JVI.80.8.4174-4178.2006

K. Chandran, N. J. Sullivan, U. Felbor, and S. P. Whelan, Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection, Science, vol.308, issue.5728, pp.308-1643, 2005.
DOI : 10.1126/science.1110656

J. E. Carette, M. Raaben, A. C. Wong, A. S. Herbert, G. Obernosterer et al., Ebola virus entry requires the cholesterol transporter Niemann???Pick C1, Nature, vol.107, issue.7364, pp.477-340, 2011.
DOI : 10.1038/nature10348

M. Côté, J. Misasi, T. Ren, A. Bruchez, K. Lee et al., Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection, Nature, vol.103, issue.7364, pp.477-344, 2011.

L. T. Jae, M. Raaben, A. S. Herbert, A. I. Kuehne, A. S. Wirchnianski et al., Lassa virus entry requires a trigger-induced receptor switch, Science, vol.344, issue.6191, pp.344-1506, 2014.
DOI : 10.1126/science.1252480

S. M. Gregory, E. Harada, B. Liang, and S. E. Delos, Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2, Proceedings of the National Academy of Science of the USA, pp.11211-11216, 2011.
DOI : 10.1073/pnas.1104760108

N. Biedenkopf, B. Hartlieb, T. Hoenen, and S. Becker, Phosphorylation of Ebola Virus VP30 Influences the Composition of the Viral Nucleocapsid Complex: IMPACT ON VIRAL TRANSCRIPTION AND REPLICATION, Journal of Biological Chemistry, vol.288, issue.16, pp.11165-11174, 2013.
DOI : 10.1074/jbc.M113.461285

P. D. Bieniasz, Late budding domains and host proteins in enveloped virus release, Virology, vol.344, issue.1, pp.55-63, 2006.
DOI : 10.1016/j.virol.2005.09.044

J. Martin-serrano, T. Zang, and P. D. Bieniasz, HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress, Nature Medicine, vol.7, issue.12, pp.1313-1319, 2001.
DOI : 10.1038/nm1201-1313

T. Noda, H. Sagara, E. Suzuki, A. Takada, H. Kida et al., Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP, Journal of Virology, vol.76, issue.10, pp.76-4855, 2002.
DOI : 10.1128/JVI.76.10.4855-4865.2002

J. Timmins, G. Schoehn, S. Ricard-blum, S. Scianimanico, T. Vernet et al., Ebola Virus Matrix Protein VP40 Interaction with Human Cellular Factors Tsg101 and Nedd4, Journal of Molecular Biology, vol.326, issue.2, pp.493-502, 2003.
DOI : 10.1016/S0022-2836(02)01406-7

URL : https://hal.archives-ouvertes.fr/hal-00313940

E. Adu-gyamfi, M. A. Digman, E. Gratton, and R. V. Stahelin, Single-Particle Tracking Demonstrates that Actin Coordinates the Movement of the Ebola Virus Matrix Protein, Biophysical Journal, vol.103, issue.9, pp.41-43, 2012.
DOI : 10.1016/j.bpj.2012.09.026

J. S. Towner, X. Pourrut, C. G. Albariño, C. N. Nkogue, B. H. Bird et al., Marburg Virus Infection Detected in a Common African Bat, PLoS ONE, vol.303, issue.8, p.764, 2007.
DOI : 10.1371/journal.pone.0000764.t001

J. S. Towner, B. R. Amman, T. K. Sealy, S. A. Carroll, J. A. Comer et al., Isolation of Genetically Diverse Marburg Viruses from Egyptian Fruit Bats, PLoS Pathogens, vol.179, issue.7, p.1000536, 2009.
DOI : 10.1371/journal.ppat.1000536.s001

J. M. Morvan, E. Nakouné, V. Deubel, and M. Colyn, Ecosystèmes forestiers et virus Ebola, Bull. Soc. Pathol. Exot, issue.3, pp.93-172, 2000.

R. Biek, P. D. Walsh, E. M. Leroy, and L. A. Real, Recent Common Ancestry of Ebola Zaire Virus Found in a Bat Reservoir, PLoS Pathogens, vol.2, issue.10, 2006.
DOI : 1080-6040(1996)002[0321:EIOPAA]2.0.CO;2

J. M. Morvan, V. Deubel, P. Gounon, E. Nakouné, P. Barrière et al., Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic, Microbes and infection, pp.1193-1201, 1999.

P. Klenerman, H. Hengartner, and R. M. Zinkernagel, A non-retroviral RNA virus persists in DNA form, Nature, issue.6657, pp.390-298, 1997.

D. J. Taylor, R. W. Leach, and J. Bruenn, Filoviruses are ancient and integrated into mammalian genomes, BMC Evolutionary Biology, vol.10, issue.1, p.193, 2010.
DOI : 10.1186/1471-2148-10-193

É. Leroy, X. Pourrut, and J. P. Gonzalez, Les chauves-souris, réservoirs du virus Ebola: Le mystère se dissipe, M/S: médecine sciences, pp.78-79, 2006.
DOI : 10.1051/medsci/200622178

URL : http://www.erudit.org/revue/ms/2006/v22/n1/012237ar.pdf

D. G. Bausch, J. S. Towner, S. F. Dowell, F. Kaducu, M. Lukwiya et al., Assessment of the Risk of Ebola Virus Transmission from Bodily Fluids and Fomites, The Journal of Infectious Diseases, vol.196, issue.s2, pp.142-147, 2007.
DOI : 10.1086/520545

P. Richards, J. Amara, M. C. Ferme, P. Kamara, E. Mokuwa et al., Social Pathways for Ebola Virus Disease in Rural Sierra Leone, and Some Implications for Containment, PLOS Neglected Tropical Diseases, vol.371, issue.440, p.3567, 2015.
DOI : 10.1371/journal.pntd.0003567.s007

K. E. Rogstad and A. Tunbridge, Ebola virus as a sexually transmitted infection, Current opinion in infectious diseases, pp.83-85, 2015.

J. B. Varkey, J. G. Shantha, I. Crozier, C. S. Kraft, G. M. Lyon et al., Persistence of Ebola Virus in Ocular Fluid during Convalescence, New England Journal of Medicine, vol.372, issue.25, pp.372-2423, 2015.
DOI : 10.1056/NEJMoa1500306

M. J. Turell, D. S. Bressler, and C. A. Rossi, Short report: lack of virus replication in arthropods after intrathoracic inoculation of Ebola Reston virus, The American journal of tropical medicine and hygiene, pp.89-90, 1996.

E. Johnson, N. Jaax, J. White, and P. Jahrling, Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus, International journal of experimental pathology, vol.132, issue.764, p.227, 1995.

Y. Suzuki and T. Gojobori, Ecologie des Ebolavirus: http://www.cdc.gov/vhf/ebola/resources/virus-ecology-fr.html The origin and evolution of Ebola and Marburg viruses, Molecular Biology and Evolution, vol.134, issue.8, pp.14-800, 1997.

Y. H. Li and S. P. Chen, Evolutionary history of Ebola virus, Epidemiology and Infection, vol.56, issue.06, pp.1138-1145, 2014.
DOI : 10.1371/journal.pone.0021740

L. Rodriguez, D. Roo-a, Y. Guimard, S. Trappier, and . Sanchez-a, Persistence and Genetic Stability of Ebola Virus during the Outbreak in Kikwit, Democratic Republic of the Congo, 1995, The Journal of Infectious Diseases, vol.179, issue.s1, pp.170-176, 1995.
DOI : 10.1086/514291

S. Wohl, Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak, Science, issue.6202, pp.345-1369, 2014.

M. G. Kortepeter, D. G. Bausch, and M. Bray, Basic Clinical and Laboratory Features of Filoviral Hemorrhagic Fever, Journal of Infectious Diseases, vol.204, issue.suppl 3, pp.810-816, 2011.
DOI : 10.1093/infdis/jir299

M. A. Bwaka, M. J. Bonnet, P. Calain, R. Colebunders, A. De-roo et al., Ebola Hemorrhagic Fever in Kikwit, Democratic Republic of the Congo: Clinical Observations in 103 Patients, The Journal of Infectious Diseases, vol.179, issue.s1, pp.1-7, 1999.
DOI : 10.1086/514308

M. Bray and T. W. Geisbert, Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever, The international journal of biochemistry & cell biology, pp.37-1560, 2005.

T. W. Geisbert, L. E. Hensley, T. Larsen, H. A. Young, D. S. Reed et al., Pathogenesis of Ebola Hemorrhagic Fever in Cynomolgus Macaques, The American Journal of Pathology, vol.163, issue.6, pp.2347-2370, 2003.
DOI : 10.1016/S0002-9440(10)63591-2

L. Falasca, C. Agrati, N. Petrosillo, D. Caro, A. Capobianchi et al., Molecular mechanisms of Ebola virus pathogenesis: focus on cell death, Cell Death and Differentiation, vol.824, issue.8, pp.22-1250, 2015.
DOI : 10.1371/journal.pone.0051548

S. Mahanty and M. Bray, Pathogenesis of filoviral haemorrhagic fevers, The Lancet infectious diseases, pp.487-498, 2004.

I. Messaoudi, G. K. Amarasinghe, and C. F. Basler, Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus, Nature Reviews Microbiology, vol.344, issue.11, pp.13-663, 2015.
DOI : 10.1038/nrmicro3524

N. Wauquier, P. Becquart, C. Padilla, S. Baize, and E. M. Leroy, Human Fatal Zaire Ebola Virus Infection Is Associated with an Aberrant Innate Immunity and with Massive Lymphocyte Apoptosis, PLoS Neglected Tropical Diseases, vol.20, issue.10, p.837, 2010.
DOI : 10.1371/journal.pntd.0000837.s002

T. W. Geisbert, H. A. Young, P. Jahrling, K. Davis, T. Larsen et al., Pathogenesis of Ebola Hemorrhagic Fever in Primate Models, The American Journal of Pathology, vol.163, issue.6, p.2371, 2003.
DOI : 10.1016/S0002-9440(10)63592-4

. Center-for-disease, D. Control, E. M. Leroy, S. Baize, C. Y. Lu et al., Diagnosis of Ebola haemorrhagic fever by RT?PCR in an epidemic setting, Journal of medical virology, vol.151, issue.604, pp.463-467, 2000.

Y. Yang, L. Bai, K. X. Hu, Z. H. Yang, J. P. Hu et al., Multiplex real-time PCR method for rapid detection of Marburg virus and Ebola virus, Chinese journal of experimental and clinical virology, vol.26, issue.4, pp.313-315, 2012.

J. S. Towner, P. E. Rollin, D. G. Bausch, A. Sanchez, S. M. Crary et al., Rapid Diagnosis of Ebola Hemorrhagic Fever by Reverse Transcription-PCR in an Outbreak Setting and Assessment of Patient Viral Load as a Predictor of Outcome, Journal of Virology, vol.78, issue.8, pp.78-4330, 2004.
DOI : 10.1128/JVI.78.8.4330-4341.2004

T. G. Ksiazek, C. P. West, P. E. Rollin, P. B. Jahrling, and C. J. Peters, ELISA for the Detection of Antibodies to Ebola Viruses, The Journal of Infectious Diseases, vol.179, issue.s1, pp.192-198, 1999.
DOI : 10.1086/514313

M. J. Broadhurst and J. D. Kelly, Ebola, le test Ezyscreen fait ses preuves sur le terrain: http://www.inserm.fr/espace-journalistes/diagnostic-rapide-d-ebola-le-test-ezyscreen-r-fait- ses-preuves-sur-le-terrain

J. Yasuda, Rapid and simple detection of Ebola virus by reverse transcription-loopmediated isothermal amplification, Journal of virological methods, vol.141, issue.1, pp.78-83, 2007.

R. T. Emond, B. Evans, E. T. Bowen, and G. Llyod, A case of Ebola virus infection., BMJ, vol.2, issue.6086, pp.541-544, 1977.
DOI : 10.1136/bmj.2.6086.541

K. Mupapa, M. Massamba, and K. Kibadi, Treatment of Ebola Hemorrhagic Fever with Blood Transfusions from Convalescent Patients, The Journal of Infectious Diseases, vol.179, issue.s1, pp.18-23, 1999.
DOI : 10.1086/514298

R. F. Sadek, A. S. Khan, G. Stevens, C. J. Peters, and T. G. Ksiazek, Ebola Hemorrhagic Fever, Democratic Republic of the Congo, 1995: Determinants of Survival, The Journal of Infectious Diseases, vol.179, issue.s1, pp.24-27, 1999.
DOI : 10.1086/514311

P. B. Jahrling, J. B. Geisbert, J. R. Swearengen, T. Larsen, and T. W. Geisbert, Ebola Hemorrhagic Fever: Evaluation of Passive Immunotherapy in Nonhuman Primates, The Journal of Infectious Diseases, vol.196, issue.s2, pp.400-403, 2007.
DOI : 10.1086/520587

J. Van-griensven, T. Edwards, and X. De-lamballerie, Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea, New England Journal of Medicine, vol.374, issue.1, pp.33-42, 2016.
DOI : 10.1056/NEJMoa1511812

URL : https://hal.archives-ouvertes.fr/hal-01252702

S. Baize, E. M. Leroy, M. C. Georges-courbot, M. Capron, and J. Lansoud-soukate, Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients, Nature Medicine, vol.5, issue.4, pp.423-426, 1999.
DOI : 10.1038/7422

I. V. Borisevich, V. V. Mickhailov, and V. P. Krasnianskii, Development and study of the properties of immunoglobulin against Ebola fever, Voprosy Virusologii, issue.6, pp.40-270, 1995.

P. B. Jahrling, J. Geisbert, and J. R. Swearengen, Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses, Archives of virology, vol.11, issue.2, pp.135-140, 1996.
DOI : 10.1007/978-3-7091-7482-1_12

N. M. Kudoyarova-zubavichene, N. N. Sergeyev, A. A. Chepurnov, and S. V. Netesov, Preparation and Use of Hyperimmune Serum for Prophylaxis and Therapy of Ebola Virus Infections, The Journal of Infectious Diseases, vol.179, issue.s1, pp.218-223, 1999.
DOI : 10.1086/514294

J. M. Dye, A. S. Herbert, and A. I. Khuene, Post exposure antibody prophylaxis protects nonhuman primates from filovirus disease, Proceedings of the National Academy of Sciences of the United States of America, pp.5034-5039, 2012.

P. W. Parren, T. W. Geisbert, T. Maruyama, P. B. Jahrling, and D. R. Burton, Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody, Journal of Virology, vol.76, issue.12, pp.6408-6412, 2002.
DOI : 10.1128/JVI.76.12.6408-6412.2002

W. B. Oswald, T. W. Geisbert, and K. J. Davis, Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys, PLoS Pathogens, vol.141, issue.1, 2007.
DOI : 1537-6613(1980)141[0580:LVIORM]2.0.CO;2

X. Qui, J. Audet, and G. Wong, Successful treatment of Ebola virusinfected cynomolgus macaques with monoclonal antibodies Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb, Science Translational Medicine, vol.4178, issue.3, pp.138-81, 2012.

X. Qui, G. Wong, and L. Fernando, Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virusinfected guinea pigs, Journal of Virology, vol.87, issue.13, pp.7754-7757, 2013.

G. G. Olinger, . Jr, J. Pettitt, and D. Kim, Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques, Proceedings of the National Academy of Sciences of the United States of America, pp.18030-18035, 2012.
DOI : 10.1073/pnas.1213709109

J. Pettitt, L. Zeitlin, D. H. Kim, C. Working, J. C. Johnson et al., Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail, Science Translational Medicine, vol.5, issue.199, pp.199-113, 0199.
DOI : 10.1126/scitranslmed.3006608

X. Qiu, G. Wong, and J. Audet, Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp, Nature, vol.27, issue.7520, pp.514-561, 2014.
DOI : 10.1086/514305

Z. Yunfang, L. Dapeng, J. Xia, and H. Zhong, Fighting Ebola with ZMapp: spotlight on plant-made antibody, Science China Life Sciences, issue.10, pp.57-987, 2014.

C. D. Murin, M. L. Fusco, Z. A. Bornholdt, and X. Qiu, Structures of protective antibodies reveal sites of vulnerability on Ebola virus, Current Issue, pp.111-17182, 2014.

. Favipiravir, T-705), a novel viral RNA polymerase inhibitor, Antiviral research, vol.100, issue.2, pp.446-454

J. S. Richardson, G. Wong, S. Pillet, S. Schindle, J. Ennis et al., Evaluation of different strategies for post-exposure treatment of Ebola virus infection in rodents, 2011.

L. Oestereich, A. Lüdtke, S. Wurr, T. Rieger, C. Muñoz-fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Research, vol.105, pp.17-21, 2014.
DOI : 10.1016/j.antiviral.2014.02.014

D. Sissoko, C. Laouenan, and E. Folkesson, Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, PLOS Medicine, vol.27, issue.1, p.1001967, 2016.
DOI : 10.1371/journal.pmed.1001967.s011

URL : https://hal.archives-ouvertes.fr/hal-01327168

T. K. Warren, J. Wells, and R. G. Panchal, Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430, Nature, vol.47, issue.7496, pp.508-402, 2014.
DOI : 10.1038/nature13027

D. F. Florescu and M. A. Keck, Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions causes by dsDNA viruses, Expert Review of Antiinfective Therapy, issue.10, pp.12-1171, 2014.

T. W. Geisbert, L. E. Hensley, and E. Kagan, Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference, The Journal of Infectious Diseases, vol.193, issue.12, pp.1650-1657, 2007.
DOI : 10.1086/504267

T. W. Geisbert, A. C. Lee, and M. Robbins, Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study, The Lancet, vol.375, issue.9729, pp.1896-1905, 2010.
DOI : 10.1016/S0140-6736(10)60357-1

K. L. Warfield, D. L. Swenson, and J. Wells, Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers, PLoS Pathogens, vol.175, issue.1, p.1, 2006.
DOI : 0022-1767(2005)175[1184:IOHACT]2.0.CO;2

T. K. Warren, K. L. Warfield, and J. Wells, Advanced antisense therapies for postexposure protection against lethal filovirus infections, Nature Medicine, vol.251, issue.9, pp.991-994, 2010.
DOI : 10.1038/nm.2202

P. L. Iversen, T. K. Warren, and J. B. Wells, Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections, Viruses, vol.4, issue.12, pp.2806-2830, 2012.
DOI : 10.3390/v4112806

L. M. Johansen, J. M. Brannan, and S. E. Delos, FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection Treatment of Ebola virus infection with a recombinant inhibitor of factor VII/tissue factor: a study in rhesus monkeys, Science Translational Medicine Lancet, vol.5, issue.362, pp.190-79, 2003.

L. E. Hensley, E. L. Stevens, and S. B. Yan, Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever, The Journal of Infectious Diseases, vol.196, issue.s2, pp.390-399, 2007.
DOI : 10.1086/520598

J. Misasi and N. J. Sullivan, Camouflage and Misdirection: The Full-On Assault of Ebola Virus Disease, Cell, vol.159, issue.3, pp.477-486, 2014.
DOI : 10.1016/j.cell.2014.10.006

W. B. Cárdenas, Y. M. Loo, M. Gale, A. L. Hartman, C. R. Kimberlin et al., Ebola Virus VP35 Protein Binds Double-Stranded RNA and Inhibits Alpha/Beta Interferon Production Induced by RIG-I Signaling, Journal of Virology, vol.80, issue.11, pp.80-5168, 2006.
DOI : 10.1128/JVI.02199-05

C. F. Basler, A. Mikulasova, L. Martinez-sobrido, J. Paragas, E. Mühlberger et al., The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3, Journal of Virology, vol.77, issue.14, pp.77-7945, 2003.
DOI : 10.1128/JVI.77.14.7945-7956.2003

L. W. Leung, A. L. Hartman, O. Martinez, M. L. Shaw, C. Carbonnelle et al., Ebola virus VP24 binds karyopherin ?1 and blocks STAT1 nuclear accumulation, Journal of virology, issue.11, pp.80-5156, 2006.

Z. Feng, M. Cerveny, Z. Yan, and B. He, The VP35 Protein of Ebola Virus Inhibits the Antiviral Effect Mediated by Double-Stranded RNA-Dependent Protein Kinase PKR, Journal of Virology, vol.81, issue.1, pp.182-192, 2007.
DOI : 10.1128/JVI.01006-06

R. L. Kaletsky, J. R. Francica, C. Agrawal-gamse, and P. Bates, Tetherinmediated restriction of filovirus budding is antagonized by the Ebola glycoprotein, Proceedings of the National Academy of Sciences, pp.2886-2891, 2009.

A. Kühl, C. Banning, A. Marzi, J. Votteler, I. Steffen et al., The Ebola Virus Glycoprotein and HIV-1 Vpu Employ Different Strategies to Counteract the Antiviral Factor Tetherin, Journal of Infectious Diseases, vol.204, issue.suppl 3, pp.850-860, 2011.
DOI : 10.1093/infdis/jir378

N. M. Lubaki, P. Ilinykh, C. Pietzsch, B. Tigabu, A. N. Freiberg et al., The Lack of Maturation of Ebola Virus-Infected Dendritic Cells Results from the Cooperative Effect of at Least Two Viral Domains, Journal of Virology, vol.87, issue.13, pp.7471-7485, 2013.
DOI : 10.1128/JVI.03316-12

K. L. Warfield, J. G. Perkins, D. L. Swenson, E. M. Deal, C. M. Bosio et al., Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection, The Journal of Experimental Medicine, vol.162, issue.2, pp.169-179, 2004.
DOI : 10.1126/science.1060042

J. N. Mandl and M. B. Feinberg, Robust and sustained immune activation in human Ebola virus infection: Fig. 1., Proceedings of the National Academy of Sciences, pp.4518-4519, 2015.
DOI : 10.1073/pnas.1503864112

A. K. Mcelroy, R. S. Akondy, C. W. Davis, A. H. Ellebedy, A. K. Mehta et al., Human Ebola virus infection results in substantial immune activation, Proceedings of the National Academy of Sciences, pp.112-4719, 2015.
DOI : 10.1073/pnas.1502619112

L. Zhang, H. Wang, and Y. Q. Zhang, ???????????????????????????????????????I??????????????????????????????????????????????????????????????????, Journal of Zhejiang University-SCIENCE B, vol.16, issue.1, pp.1-9, 2015.
DOI : 10.1631/jzus.B1400365

N. Wauquier, P. Becquart, C. Padilla, S. Baize, and E. M. Leroy, Human Fatal Zaire Ebola Virus Infection Is Associated with an Aberrant Innate Immunity and with Massive Lymphocyte Apoptosis, PLoS Neglected Tropical Diseases, vol.20, issue.10, p.837, 2010.
DOI : 10.1371/journal.pntd.0000837.s002

E. M. Leroy, S. Baize, V. E. Volchkov, S. P. Fisher-hoch, M. C. Georges-courbot et al., Human asymptomatic Ebola infection and strong inflammatory response, The Lancet, pp.355-2210, 2000.

A. L. Rasmussen, A. Okumura, M. T. Ferris, R. Green, F. Feldmann et al., Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance, Science, vol.346, issue.6212, pp.346-987, 2014.
DOI : 10.1126/science.1259595

G. Courcoux, Une immunité naturelle contre Ebola?, Actualité scientifique, 2010.

T. W. Geisbert and H. Feldmann, Recombinant Vesicular Stomatitis Virus-Based Vaccines Against Ebola and Marburg Virus Infections, Journal of Infectious Diseases, vol.204, issue.suppl 3, pp.1075-1081, 2011.
DOI : 10.1093/infdis/jir349

J. R. Garon and W. A. Orenstein, Understanding the host???pathogen interaction saves lives: lessons from vaccines and vaccinations, Current Opinion in Immunology, vol.36, pp.8-13, 2015.
DOI : 10.1016/j.coi.2015.04.003

L. Ye and C. Yang, Development of vaccines for prevention of Ebola virus infection, Microbes and Infection, vol.17, issue.2, pp.98-108, 2015.
DOI : 10.1016/j.micinf.2014.12.004

Y. Zhou and N. J. Sullivan, Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine, Current Opinion in Immunology, vol.35, pp.131-136, 2015.
DOI : 10.1016/j.coi.2015.06.006

M. Hevey, D. Negley, J. Geisbert, P. Jahrling, and A. Schmaljohn, Antigenicity and Vaccine Potential of Marburg Virus Glycoprotein Expressed by Baculovirus Recombinants, Virology, vol.239, issue.1, pp.239-206, 1997.
DOI : 10.1006/viro.1997.8883

P. R. Krause, P. R. Bryant, T. Clark, W. Dempsey, E. Henchal et al., Immunology of protection from Ebola virus infection, Science Translational Medicine, vol.7, issue.286, pp.286-297, 2015.
DOI : 10.1126/scitranslmed.aaa8202

P. Halfmann, J. H. Kim, H. Ebihara, T. Noda, G. Neumann et al., Generation of biologically contained Ebola viruses, Proceedings of the National Academy of Sciences, pp.1129-1133, 2008.
DOI : 10.1073/pnas.0708057105

P. Halfmann, H. Ebihara, A. Marzi, Y. Hatta, S. Watanabe et al., Replication-Deficient Ebolavirus as a Vaccine Candidate, Journal of Virology, vol.83, issue.8, pp.83-3810, 2009.
DOI : 10.1128/JVI.00074-09

A. Marzi, P. Halfmann, L. Hill-batorski, F. Feldmann, W. L. Shupert et al., An Ebola whole-virus vaccine is protective in nonhuman primates, Science, vol.348, issue.6233, pp.348-439, 2015.
DOI : 10.1126/science.aaa4919

H. Lupton, R. Lambert, D. Bumgardner, J. Moe, and G. Eddy, Inactivated vaccine for Ebola virus efficacious in guineapig model, The Lancet, pp.316-1294, 1980.

A. A. Chupurnov, I. V. Chernukhin, V. A. Ternovo?, N. M. Kudoiarova, N. M. Makhova et al., Attempts to develop a vaccine against Ebola fever, Voprosy virusologii, issue.6, pp.40-257, 1994.

T. W. Geisbert, P. Pushko, K. Anderson, J. Smith, K. J. Davis et al., Evaluation in Nonhuman Primates of Vaccines against Ebola Virus, Perspectives), Emerging infectious diseases, pp.503-508, 2002.
DOI : 10.3201/eid0805.010284

K. L. Warfield, D. L. Swenson, G. G. Olinger, W. V. Kalina, M. Viard et al., Ebola Virus Inactivation with Preservation of Antigenic and Structural Integrity by a Photoinducible Alkylating Agent, The Journal of Infectious Diseases, vol.196, issue.s2, pp.276-283, 2007.
DOI : 10.1086/520605

J. L. Mellquist-riemenschneider, A. R. Garrison, J. B. Geisbert, K. U. Saikh, K. D. Heidebrink et al., Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs, Virus Research, vol.92, issue.2, pp.187-193, 2003.
DOI : 10.1016/S0168-1702(02)00338-6

K. Konduru, S. B. Bradfute, J. Jacques, M. Manangeeswaran, S. Nakamura et al., Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice, Vaccine, vol.29, issue.16, pp.29-2968, 2011.
DOI : 10.1016/j.vaccine.2011.01.113

R. Noad and P. Roy, Virus-like particles as immunogens, Trends in Microbiology, vol.11, issue.9, pp.438-444, 2003.
DOI : 10.1016/S0966-842X(03)00208-7

T. Noda, H. Sagara, E. Suzuki, A. Takada, H. Kida et al., Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP, Journal of Virology, vol.76, issue.10, pp.76-4855, 2002.
DOI : 10.1128/JVI.76.10.4855-4865.2002

K. L. Warfield, C. M. Bosio, B. C. Welcher, E. M. Deal, M. Mohamadzadeh et al., Ebola virus-like particles protect from lethal Ebola virus infection, Proceedings of the National Academy of Sciences, pp.15889-15894, 2003.
DOI : 10.1073/pnas.2237038100

L. Ye, J. Lin, Y. Sun, S. Bennouna, M. Lo et al., Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies, Virology, vol.351, issue.2, pp.351-260, 2006.
DOI : 10.1016/j.virol.2006.03.021

K. L. Warfield, G. Olinger, E. M. Deal, D. L. Swenson, M. Bailey et al., Induction of Humoral and CD8+ T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection, The Journal of Immunology, vol.175, issue.2, pp.1184-1191, 2005.
DOI : 10.4049/jimmunol.175.2.1184

K. L. Warfield, D. L. Swenson, G. Demmin, and S. Bavari, Filovirus-like particles as vaccines and discovery tools, Expert review of vaccines, pp.429-440, 2005.

D. L. Swenson, K. L. Warfield, D. L. Negley, A. Schmaljohn, M. J. Aman et al., Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections, Vaccine, vol.23, issue.23, pp.23-3033, 2005.
DOI : 10.1016/j.vaccine.2004.11.070

K. L. Warfield, N. A. Posten, D. L. Swenson, G. G. Olinger, D. Esposito et al., Filovirus???Like Particles Produced in Insect Cells: Immunogenicity and Protection in Rodents, The Journal of Infectious Diseases, vol.196, issue.s2, pp.421-429, 2007.
DOI : 10.1086/520612

A. D. Vaccins, L'apport des nouvelles technologies en vaccinologie, médecine/sciences, pp.386-90, 2007.

D. C. Tang, M. Devit, and S. A. Johnston, Genetic immunization is a simple method for eliciting an immune response, Nature, vol.356, issue.6365, pp.356-152, 1992.
DOI : 10.1038/356152a0

D. B. Lowe, M. H. Shearer, and R. C. Kennedy, DNA vaccines: Successes and limitations in cancer and infectious disease, Journal of Cellular Biochemistry, vol.201, issue.2, pp.235-242, 2006.
DOI : 10.1002/jcb.20775

N. J. Sullivan, A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel, Development of a preventive vaccine for Ebola virus infection in primates, Nature, issue.6812, pp.408-605, 2000.

L. E. Hensley, S. Mulangu, C. Asiedu, J. Johnson, A. N. Honko et al., Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species, PLoS Pathogens, vol.4, issue.5, p.1000904, 2010.
DOI : 10.1371/journal.ppat.1000904.g004

H. Kibuuka, N. M. Berkowitz, M. Millard, M. E. Enama, A. Tindikahwa et al., Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial, The Lancet, vol.385, issue.9977, pp.385-1545, 2015.
DOI : 10.1016/S0140-6736(14)62385-0

S. Bertagnoli, B. Pignolet, S. Biacchesi, M. Eloit, B. Klonjkowski et al., Les vecteurs viraux: outils modernes de vaccination, pp.127-126, 2008.

Y. Choi and J. Chang, Viral vectors for vaccine applications, Clinical and experimental vaccine research, pp.97-105, 2013.

G. G. Olinger, M. A. Bailey, J. M. Dye, R. Bakken, A. Kuehne et al., Protective Cytotoxic T-Cell Responses Induced by Venezuelan Equine Encephalitis Virus Replicons Expressing Ebola Virus Proteins, Journal of Virology, vol.79, issue.22, pp.79-14189, 2005.
DOI : 10.1128/JVI.79.22.14189-14196.2005

M. Hevey, D. Negley, P. Pushko, J. Smith, and A. Schmaljohn, Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates, Virology, vol.251, issue.1, pp.251-279, 1998.
DOI : 10.1006/viro.1998.9367

A. S. Herbert, A. I. Kuehne, J. F. Barth, R. A. Ortiz, D. K. Nichols et al., Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Protects Nonhuman Primates from Intramuscular and Aerosol Challenge with Ebolavirus, Journal of Virology, vol.87, issue.9, pp.4952-4964, 2013.
DOI : 10.1128/JVI.03361-12

O. Reynard, V. Mokhonov, E. Mokhonova, J. Leung, A. Page et al., Kunjin Virus Replicon-Based Vaccines Expressing Ebola Virus Glycoprotein GP Protect the Guinea Pig Against Lethal Ebola Virus Infection, Journal of Infectious Diseases, vol.204, issue.suppl 3, pp.1060-1065, 2011.
DOI : 10.1093/infdis/jir347

A. Bukreyev, L. Yang, S. R. Zaki, W. J. Shieh, P. E. Rollin et al., A Single Intranasal Inoculation with a Paramyxovirus-Vectored Vaccine Protects Guinea Pigs against a Lethal-Dose Ebola Virus Challenge, Journal of Virology, vol.80, issue.5, pp.2267-2279, 2006.
DOI : 10.1128/JVI.80.5.2267-2279.2006

A. Bukreyev, J. M. Dinapoli, L. Yang, B. R. Murphy, and P. L. Collins, Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic, Virology, vol.399, issue.2, pp.399-290, 2010.
DOI : 10.1016/j.virol.2010.01.015

J. M. Dinapoli, L. Yang, S. K. Samal, B. R. Murphy, P. L. Collins et al., Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response, Vaccine, vol.29, issue.1, pp.29-46, 2010.
DOI : 10.1016/j.vaccine.2010.10.024

J. E. Blaney, C. Wirblich, A. B. Papaneri, R. F. Johnson, C. J. Myers et al., Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses, Journal of Virology, vol.85, issue.20, pp.85-10605, 2011.
DOI : 10.1128/JVI.00558-11

A. Chepurnov, V. Ternovoi, A. Dadayeva, I. Dmitriyev, L. Sizikova et al., Study of immunobiological properties of Ebola virus VP24 protein expressed by recombinant vaccinia virus, Voprosy Virusologii, vol.42, pp.115-120, 1997.

Y. Tsuda, P. Caposio, C. J. Parkins, S. Botto, I. Messaoudi et al., A Replicating Cytomegalovirus-Based Vaccine Encoding a Single Ebola Virus Nucleoprotein CTL Epitope Confers Protection against Ebola Virus, PLoS Neglected Tropical Diseases, vol.90, issue.Pt 2, p.1275, 2011.
DOI : 10.1371/journal.pntd.0001275.s004

Y. Tsuda, C. J. Parkins, P. Caposio, F. Feldmann, S. Botto et al., A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose, Vaccine, vol.33, issue.19, pp.33-2261, 2015.
DOI : 10.1016/j.vaccine.2015.03.029

A. Marzi, A. A. Murphy, F. Feldmann, C. J. Parkins, E. Haddock et al., Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection, Scientific Reports, vol.4, issue.1, 2016.
DOI : 10.1371/journal.pone.0005547

N. Tatsis and H. C. Ertl, Adenoviruses as vaccine vectors, Molecular Therapy, vol.10, issue.4, pp.616-629, 2004.
DOI : 10.1016/j.ymthe.2004.07.013

N. J. Sullivan, T. W. Geisbert, J. B. Geisbert, L. Xu, Z. Y. Yang et al., Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates, Nature, vol.424, issue.6949, pp.424-681, 2003.
DOI : 10.1038/nature01876

W. D. Pratt, D. Wang, D. K. Nichols, M. Luo, J. Woraratanadharm et al., Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector, Clinical and Vaccine Immunology, pp.572-581, 2010.

D. L. Swenson, D. Wang, M. Luo, K. L. Warfield, J. Woraratanadharm et al., Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections, Clinical and vaccine immunology, pp.460-467, 2008.

N. J. Sullivan, L. Hensley, C. Asiedu, T. W. Geisbert, D. Stanley et al., Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates, Science translational medicine Nature medicine, vol.4, issue.179, pp.158-146, 2011.

K. Mccoy, N. Tatsis, B. Korioth-schmitz, M. O. Lasaro, S. E. Hensley et al., Effect of Preexisting Immunity to Adenovirus Human Serotype 5 Antigens on the Immune Responses of Nonhuman Primates to Vaccine Regimens Based on Human- or Chimpanzee-Derived Adenovirus Vectors, Journal of Virology, vol.81, issue.12, pp.81-6594, 2007.
DOI : 10.1128/JVI.02497-06

F. C. Zhu, L. H. Hou, J. X. Li, S. P. Wu, P. Liu et al., Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial, The Lancet, vol.385, issue.9984, pp.385-2272, 2015.
DOI : 10.1016/S0140-6736(15)60553-0

A. Patel, Y. Zhang, M. Croyle, K. Tran, M. Gray et al., Mucosal Delivery of Adenovirus???Based Vaccine Protects against Ebola Virus Infection in Mice, The Journal of Infectious Diseases, vol.196, issue.s2, pp.413-420, 2007.
DOI : 10.1086/520603

J. S. Richardson, S. Pillet, A. J. Bello, and G. P. Kobinger, Airway Delivery of an Adenovirus-Based Ebola Virus Vaccine Bypasses Existing Immunity to Homologous Adenovirus in Nonhuman Primates, Journal of Virology, vol.87, issue.7, pp.3668-3677, 2013.
DOI : 10.1128/JVI.02864-12

T. W. Geisbert, M. Bailey, L. Hensley, C. Asiedu, J. Geisbert et al., Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge, Journal of Virology, vol.85, issue.9, pp.4222-4233, 2011.
DOI : 10.1128/JVI.02407-10

G. P. Kobinger, H. Feldmann, Y. Zhi, G. Schumer, G. Gao et al., Chimpanzee adenovirus vaccine protects against Zaire Ebola virus, Virology, vol.346, issue.2, pp.346-394, 2006.
DOI : 10.1016/j.virol.2005.10.042

D. A. Stanley, A. N. Honko, C. Asiedu, J. C. Trefry, A. W. Lau-kilby et al., Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge, Nature Medicine, vol.7, 2014.
DOI : 10.1038/nm.3702

Q. Zhang and D. Seto, Chimpanzee adenovirus vector Ebola vaccine? preliminary report, The New England journal of medicine, vol.373, issue.8, pp.775-776, 2015.

T. Rampling, K. Ewer, G. Bowyer, D. Wright, E. B. Imoukhuede et al., A monovalent chimpanzee adenovirus Ebola vaccine?preliminary report, 2015.

A. Marzi, H. Feldmann, T. W. Geisbert, and D. Falzarano, Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections, Journal of Bioterrorism & Biodefense, vol.01, issue.01, 2011.
DOI : 10.4172/2157-2526.S1-004

T. W. Geisbert and H. Feldmann, Recombinant Vesicular Stomatitis Virus-Based Vaccines Against Ebola and Marburg Virus Infections, Journal of Infectious Diseases, vol.204, issue.suppl 3, pp.1075-1081, 2011.
DOI : 10.1093/infdis/jir349

S. M. Jones, H. Feldmann, U. Ströher, J. B. Geisbert, L. Fernando et al., Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses, Nature Medicine, vol.179, issue.7, pp.11-786, 2005.
DOI : 10.1016/S0140-6736(82)91871-2

T. W. Geisbert, K. M. Daddario-dicaprio, J. B. Geisbert, D. S. Reed, F. Feldmann et al., Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses, Vaccine, vol.26, issue.52, pp.26-6894, 2008.
DOI : 10.1016/j.vaccine.2008.09.082

X. Qiu, L. Fernando, J. B. Alimonti, P. L. Melito, F. Feldmann et al., Mucosal Immunization of Cynomolgus Macaques with the VSV??G/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses, PLoS ONE, vol.79, issue.4, p.5547, 2009.
DOI : 10.1371/journal.pone.0005547.t001

C. E. Mire, J. B. Geisbert, K. N. Agans, B. A. Satterfield, K. M. Versteeg et al., Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates, PLoS ONE, vol.196, issue.4, p.94355, 2014.
DOI : 10.1371/journal.pone.0094355.s001

H. Feldmann, S. M. Jones, K. M. Daddario-dicaprio, J. B. Geisbert, U. Ströher et al., Effective Post-Exposure Treatment of Ebola Infection, PLoS Pathogens, vol.56, issue.1, p.2, 2007.
DOI : 10.1371/journal.ppat.0030002.sg002

T. W. Geisbert, K. M. Daddario-dicaprio, K. J. Williams, J. B. Geisbert, A. Leung et al., Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman Primates, Journal of Virology, vol.82, issue.11, pp.82-5664, 2008.
DOI : 10.1128/JVI.00456-08

K. M. Daddario-dicaprio, T. W. Geisbert, U. Ströher, J. B. Geisbert, A. Grolla et al., Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment, The Lancet, vol.367, issue.9520, pp.367-1399, 2006.
DOI : 10.1016/S0140-6736(06)68546-2

A. Marzi, S. J. Robertson, E. Haddock, F. Feldmann, P. W. Hanley et al., VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain, Science, vol.349, issue.6249, pp.349-739, 2015.
DOI : 10.1126/science.aab3920

T. W. Geisbert, D. G. Bausch, and H. Feldmann, Prospects for immunisation against Marburg and Ebola viruses, Reviews in Medical Virology, vol.78, issue.Suppl 2, pp.344-357, 2010.
DOI : 10.1002/rmv.661

D. Falzarano, F. Feldmann, A. Grolla, A. Leung, H. Ebihara et al., Single Immunization With a Monovalent Vesicular Stomatitis Virus-Based Vaccine Protects Nonhuman Primates Against Heterologous Challenge With Bundibugyo ebolavirus, Journal of Infectious Diseases, vol.204, issue.suppl 3, pp.1082-1089, 2011.
DOI : 10.1093/infdis/jir350

A. Marzi, H. Ebihara, J. Callison, A. Groseth, K. J. Williams et al., Vesicular Stomatitis Virus-Based Ebola Vaccines With Improved Cross-Protective Efficacy, Journal of Infectious Diseases, vol.204, issue.suppl 3, pp.1066-1074, 2011.
DOI : 10.1093/infdis/jir348

T. W. Geisbert, J. B. Geisbert, A. Leung, K. M. Daddario-dicaprio, L. E. Hensley et al., Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus, Journal of Virology, vol.83, issue.14, pp.83-7296, 2009.
DOI : 10.1128/JVI.00561-09

J. E. Johnson, F. Nasar, J. W. Coleman, R. E. Price, A. Javadian et al., Neurovirulence properties of recombinant vesicular stomatitis virus vectors in nonhuman primates, Virology, issue.1, pp.360-396, 2007.

C. E. Mire, A. D. Miller, A. Carville, S. V. Westmoreland, J. B. Geisbert et al., Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates, PLoS Neglected Tropical Diseases, vol.196, issue.3, p.1567, 2012.
DOI : 10.1371/journal.pntd.0001567.t004

T. W. Geisbert, K. M. Daddario-dicaprio, M. G. Lewis, J. B. Geisbert, A. Grolla et al., Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates, PLoS Pathogens, vol.76, issue.9, p.1000225, 2008.
DOI : 10.1371/journal.ppat.1000225.t004

A. Marzi, F. Engelmann, F. Feldmann, K. Haberthur, W. L. Shupert et al., Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates, Proceedings of the National Academy of Sciences, pp.1893-1898, 2013.
DOI : 10.1073/pnas.1209591110

S. T. Agnandji, A. Huttner, M. E. Zinser, P. Njuguna, C. Dahlke et al., Phase 1 trials of rVSV Ebola vaccine in Africa and Europe?preliminary report, 2015.

J. A. Regules, J. H. Beigel, K. M. Paolino, J. Voell, A. R. Castellano et al., A recombinant vesicular stomatitis virus Ebola vaccine?preliminary report, 2015.